Addressing the Role of PARP Inhibitors in Different Breast Cancer Settings
Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.
Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.
Recent research has led to the availability of numerous drugs for the treatment of HER2+ breast cancer, while PARP inhibitors are only the first targeted therapy for triple-negative breast cancer to meet a primary endpoint. These will be tested in a variety of combinations in the future, Litton predicts.
PARP inhibitors are currently only being used in cases of metastatic breast cancer with aBRCAgermline mutation. But, Litton notes, we cannot forget about ER+ breast cancer as well, even though there are only a small percent of these patients with aBRCAgermline mutation.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
